Activated Charcoal Use in Chronic Kidney Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-31

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia

NCT02836184

Hyperphosphatemia

UNKNOWN PHASE4

Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous

NCT04311645

Chronic Kidney Disease stage3

UNKNOWN PHASE2

Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

NCT00458289

Hyperphosphatemia in Chronic Kidney Disease

COMPLETED PHASE1

Hyperphosphatemia in Children With Chronic Kidney Disease

NCT03202407

Hyperphosphatemia

UNKNOWN PHASE3

Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients

NCT05577507

Chronic Kidney Diseases Hemodialysis Complication Hyperphosphatemia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease (ESRD) CKD 5D, Hemodialysis CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

patients receiving standard care therapy of calcium-based or non-calcium based (sevelamer) binders.

Group Type OTHER

Phosphate Binders

Intervention Type DRUG

calcium-based or non-calcium based (sevelamer) binders

Intervention group

patients receiving standard care therapy of calcium-based or non-calcium based (sevelamer) binders in addition to oral activated charcoal capsules with meals

Group Type EXPERIMENTAL

Activated Charcoal

Intervention Type DRUG

oral activated charcoal capsules

Phosphate Binders

Intervention Type DRUG

calcium-based or non-calcium based (sevelamer) binders

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.